141 related articles for article (PubMed ID: 29233889)
1. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.
Magi S; Iwamoto K; Yumoto N; Hiroshima M; Nagashima T; Ohki R; Garcia-Munoz A; Volinsky N; Von Kriegsheim A; Sako Y; Takahashi K; Kimura S; Kholodenko BN; Okada-Hatakeyama M
J Biol Chem; 2018 Feb; 293(6):2206-2218. PubMed ID: 29233889
[TBL] [Abstract][Full Text] [Related]
2. Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2.
Mizutani K; Kedashiro S; Maruoka M; Ueda Y; Takai Y
Sci Rep; 2017 Sep; 7(1):11375. PubMed ID: 28900130
[TBL] [Abstract][Full Text] [Related]
3. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
4. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
5. Homo- and Heteroassociations Drive Activation of ErbB3.
Váradi T; Schneider M; Sevcsik E; Kiesenhofer D; Baumgart F; Batta G; Kovács T; Platzer R; Huppa JB; Szöllősi J; Schütz GJ; Brameshuber M; Nagy P
Biophys J; 2019 Nov; 117(10):1935-1947. PubMed ID: 31653451
[TBL] [Abstract][Full Text] [Related]
6. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
7. Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells.
Hiroshima M; Saeki Y; Okada-Hatakeyama M; Sako Y
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):13984-9. PubMed ID: 22891299
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
10. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
11. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
12. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
[TBL] [Abstract][Full Text] [Related]
13. The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway.
Takamiya R; Takahashi M; Uehara Y; Ariki S; Hashimoto J; Hasegawa Y; Kuroki Y
Biochem Biophys Res Commun; 2014 Nov; 454(3):364-8. PubMed ID: 25451255
[TBL] [Abstract][Full Text] [Related]
14. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
16. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
17. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
18. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
19. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
Fock V; Plessl K; Draxler P; Otti GR; Fiala C; Knöfler M; Pollheimer J
J Cell Sci; 2015 Dec; 128(23):4306-16. PubMed ID: 26490994
[TBL] [Abstract][Full Text] [Related]
20. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
